A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors

PURPOSE: This phase I study was conducted to evaluate the safety, tolerability, pharmacological properties and biological activity of the combination of the lonafarnib, a farnesylproteintransferase (FTPase) inhibitor, with gemcitabine and cisplatin in patients with advanced solid malignancies. EXPER...

Full description

Saved in:
Bibliographic Details
Main Authors: Chow, Laura Q. M., Eckhardt, S. Gail, O’Bryant, Cindy L., Schultz, Mary Kay, Morrow, Mark, Grolnic, Stacy, Basche, Michele, Gore, Lia
Format: Artigo
Language:Inglês
Published: 2007
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2813768/
https://ncbi.nlm.nih.gov/pubmed/18058098
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-007-0646-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items